Clinical Trial Search

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale

Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356

Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants

Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants

Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares

Primary: Uric Acid Level — 8.23; 8.03 mg/dL

Primary: Responders — 17; 28; 9 Participants

Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale

Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants

Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…

Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472

Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12) — 0.79; 0.15 Number of gout flares per participant

Primary: Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 68.0; 73.1 percentage of participants

Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant

Primary: Time to First New Flare — NA; NA Days

Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares

Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298

Primary: Adverse Event Profile — 7; 2 Number of participants

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale

Primary: Preference IVR vs RheumPRO — 3; 28 Participants